



**Freedom of Information Act 2000 - Request Reference FoI/22/083**

**Humira**

**1. How many patients were treated by your Trust in the last 3 months with the following drugs:**

Adalimumab (Amgevita)	Adalimumab (Humira)	Adalimumab (Hyrimoz)	Adalimumab (Idacio)	Adalimumab (Imraldi)
199	0	0	0	0

**2. Of the patients treated with Humira in the last 3 months, how many were new to Adalimumab treatment (patients who had not been treated with any brand of Adalimumab in the past year)? If possible please provide new patients number by:**

New Humira patients – all departments	New Humira patients – rheumatology	New Humira patients – dermatology	New Humira patients – gastroenterology

In completing a search for the information requested, Cardiff and Vale University Health Board (the UHB) has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual records and the UHB considers that this would exceed the limit set within regulations for responding to a request. The UHB has therefore relied upon the Section 12 exemption ('Exemption where cost of compliance exceeds appropriate limit') of the Freedom of Information Act 2000 and is refusing your request.

The UHB has estimated that to complete the work needed to respond to this request would exceed the time limit as set within regulations to respond to a Freedom of Information Act request. Under the Act there is an allowance of two and a half days, or 18 hours, to comply with a request and the cost limit set within the fees regulations for this amount of work (18 hours) is £450 for the UHB. The fees regulations specify that the cost of complying with a request must be calculated at the rate of £25 per hour.

**3. Of the patients treated with any Adalimumab Biosimilar (Amgevita, Hyrimoz, Idacio, Imraldi etc.) in the last 3 months, how many patients were new to Adalimumab treatment (patients who had not been treated with any brand of Adalimumab in the past year)? If possible provide new patients numbers by department:**





GIG  
CYMRU  
NHS  
WALES

Bwrdd Iechyd Prifysgol  
Caerdydd a'r Fro  
Cardiff and Vale  
University Health Board

New Adalimumab Biosimilar patients – all departments	New Adalimumab Biosimilar patients – rheumatology	New Adalimumab Biosimilar patients – dermatology	New Adalimumab Biosimilar patients – gastroenterology

Please see above.

